Programme to Improve Life and Longevity Pilot

Is a polypill tolerable and effective at improving blood pressure and cholesterol control in people at raised risk of cardiovascular disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000099426

Acronym

PILL Pilot

Enrollment

365

Registered

2007-01-30

Start date

2008-10-02

Completion date

2009-12-18

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cardiovascular disease (CVD) is the leading cause of hospitalisation and premature death in many countries globally. One of the most hotly debated issues in clinical research is whether a “polypill” (a new combination medication containing aspirin and agents to lower blood pressure and cholesterol) can really reduce cardiovascular disease by three-quarters or more. This clinical trial will assess the safety and tolerability of a polypill, and its effects on blood pressure and cholesterol in people at increased risk of CVD.

Interventions

Polypill - one tablet once a day for 12 weeks. Polypill contains aspirin 75mg, simvastatin 20mg, lisinopril 10mg and hydrochlorothiazide 12.5mg.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adults with 5-year cardiovascular risk of at least 7.5%. 2. No definite indication or contraindication for treatment with low dose aspirin, Angiotensin-Converting Enzyme (ACE) inhibitor, low-dose diuretic or statin. 3. Participant able to give informed consent

Exclusion criteria

exclusion criteria:1. Life-limiting disease or events

Outcome results